Natural polysaccharides are valued in drug delivery for their biocompatibility, biodegradability, and low immunogenicity. Many of these polymers, including chitosan, alginate, hyaluronic acid (HA), and pectin (PEC), originate from food-medicine homology resources and have a long history of safe human use. A key advantage of these polymers is their chemical versatility, which allows precise control over molecular assembly and dimensional programmability. This feature enables the construction of carriers ranging from nanoscopic colloids to macroscopic implants. Although polysaccharide-based systems have been intensively studied, most investigations have focused on chemical modifications or encapsulation strategies. The physical size of the carrier has received comparatively less systematic consideration. In this review, we propose a size-tailored classification that organizes polysaccharide delivery platforms into nanoscale, microscale, and macroscale categories, with each defined by its distinct functional role in the delivery process. Nanoscale platforms, including nanoparticles, micelles, and nanogels, are well suited for improving solubility, achieving targeted delivery, and facilitating cellular uptake after intravenous administration. Microscale systems, such as microcapsules, microspheres, and microneedles, act as localized depots that provide sustained release and minimize drug distribution to nontarget tissues. Macroscale constructs, including hydrogels, films, and tablets, accommodate large drug doses and enable site-specific application, often with enhanced patient compliance. By examining how carrier dimensions influence drug transport, tissue retention, and release dynamics, this review establishes size control as a meaningful and accessible design parameter. Therefore, this framework offers a rational basis for engineering next-generation polysaccharide-based delivery systems in the context of precision medicine.
- Article type
- Year
- Co-author
Open Access
Review Article
Online First
Open Access
Perspective
Issue
Open Access
Opinion
Issue
Open Access
Research Article
Issue
As the global population ages, the prevalence of osteosarcopenia—a combined condition of osteoporosis and sarcopenia—poses significant health challenges, leading to increased frailty, falls, and chronic disability in the elderly, especially for postmenopausal women. Nutritional interventions targeting age-associated physiological decline present promising strategies for managing these conditions. In this study, the preventive effects of total Lycium barbarum polysaccharide (LBP), acidic LBP (ALBP), and neutral LBP (NLBP) on osteosarcopenia were systematically evaluated using an ovariectomized (OVX) mouse model. Our findings showed that ALBP significantly improved physical performance, bone strength, and bone density, while enhancing muscle mass and fiber size, thereby effectively alleviating osteosarcopenia. Mechanistic investigations revealed that ALBP elevated the expression levels of osteoblast-associated genes such as Alp, Col1a1, Runx2, Opn, upregulated key myogenic genes, including Myh2, Myh4, Myh7, while activating the phosphoinositide 3 kinase-protein kinase B (PI3K-AKT) signaling pathway. Dose-response relationship studies confirmed the efficacy of ALBP in preventing osteosarcopenia. Further analysis using gut microbiota sequencing, depletion models, and correlation analysis demonstrated that the preventive effects of ALBP are strongly correlated with the gut microbiota, including Bacteroidota, Firmicutes, Desulfobacterota, and Patescibacteria. These results highlight the potential of ALBP as a promising candidate for preventing osteosarcopenia and improving the well-being of the elderly.
京公网安备11010802044758号